Cutaneous Hemangiomas Research Articles

Consumptive Hypothyroidism due to Hepatic Hemangiomas: A Case Series and Review of the Literature.

Here, we report a case series of 3 patients and a systematic review of the literature. Hypothyroidism (mean serum TSH 52.03 mIU/L) was detected at a mean age of 4.6 months (range 3-6) in 3 infants with infantile hepatic hemangiomas, treated with thyroxine (mean dose 12 µg/kg/day). All received treatment with propranolol (1-3 mg/kg/day) from the mean age of 4 months. Hormonal treatment was stopped at a mean age of 20 months (range 12-30). Hypothyroidism reoccurred in a patient concurrently with the increase of liver lesions, requiring liver transplantation (LT) at age 39 months.Literature review retrieved 42 studies (48 patients): HH (n = 43) were isolated in 24 infants and associated with cutaneous hemangiomas in 19. Hemangiomas were only cutaneous in 5.In the first 43 patients, hypothyroidism was detected at a mean age of 1 month; 21 of 43 patients were prescribed propranolol alone (n = 8) or associated with other medicaments (n = 13); 2 of 43 patients underwent LT. Hormonal treatment consisted of T4 in 35 of 43 patients and T3 in 10.CH associated with only cutaneous and extrahepatic visceral hemangiomas (n = 5), detected at a mean age of 7 months (TSH mean levels at diagnosis of 150.3 mIU/L). Three of 5 patients received treatment with propranolol ± other medicaments. All 5 patients were treated with T4. Periodical thyroid function assessment is necessary in patients with hepatic hemangiomas, particularly when lesions' size and number increase rapidly.

Prenatal ultrasonographic features and follow-up outcomes of 19 cases of congenital intrahepatic portosystemic venous shunts diagnosed during the foetal period

BackgroundTo investigate the prenatal ultrasonographic features and case characteristics of the congenital intrahepatic portosystemic venous shunt (IHPSS) diagnosed during the foetal period and analyse its prognosis.MethodsWe conducted a retrospective cohort study of patients diagnosed with IHPSS between 2016 and 2021. IHPSS was defined as an abnormal connection between the foetal intrahepatic portal and the hepatic veins.ResultsIn this study, 19 foetuses were identified, including 12 cases of single shunt and 7 cases of multiple shunts, with a gestational age of 33.8 ± 4.5 (range 25–40) weeks at diagnosis. In the single-shunt group, the origin position of the shunts was all from the left branch of the portal vein (LPV), whereas in the multiple-shunt group, the origin position of the shunts was from the LPV in six cases. Common concomitant intrauterine abnormalities of IHPSS include foetal growth restriction (47.4%) and foetal cardiac enlargement (21.1%). The postnatal manifestations of IHPSS include biochemical abnormalities (increased gamma-glutamyl transferase and bilirubin levels), neonatal hypoglycaemia, neonatal hyperammonaemia, pulmonary hypertension, multiple intrahepatic hyperechoic nodules, and cutaneous haemangiomas. Spontaneous closure of shunts occurred in ten cases, and the mean time to shunt closure was 8.1 months (1–28 months).ConclusionsMost IHPSS found during the foetal period is located in the left branch of the portal vein, and the gestational age at diagnosis is usually in the late second or third trimester. Spontaneous closure of shunts can occur in most live births, and the prognosis is good.

The prevalence and risk factors for visceral hemangiomas in children with infantile cutaneous hemangiomas

One of the most frequent benign tumor pathology in children is represented by infantile hemangiomas (IHs). Although they are mostly cutaneous, sometimes they can develop at visceral level, the liver being the most common localization. Objectives. Estimating visceral hemangiomas (VHs) prevalence, and identification of risk factors for VHs in patients with infantile cutaneous hemangiomas (ICHs). Materials and methods. 6 years cross-sectional study (2012-2017) including children diagnosed with ICHs, admitted in I.N.S.M.C “Alfred-Rusescu“. All patients underwent an ultrasound screening for the detection of VHs. In order to identify possible risk factors, we collected demographic and perinatal data. Outcomes. 138 patients diagnosed with infantile cutaneous hemangiomas (ICHs) were included, with a slight predominance of girls (58%). The prevalence of the VHs in our study was 7,24% (10 patients). The liver was the most common visceral localization (7 patients). Conclusions. Female gender, preterm birth, low birth weight, and multiple gestations were described as potential risk factors for IHs. In our study, only multiple gestations tend to be associated with visceral hemangiomas, but without a significant statistical correlation.

Surgical treatment of glaucoma with filtration bleb activation of a patient with Sturge — Weber syndrome: a clinical case

Purpose:to describe surgical treatment of glaucoma of a patient with Sturge — Weber — Krabbe syndrome. We present a clinical case of a patient with Sturge — Weber — Krabbe syndrome who sought assistance with us due to secondary stage III glaucoma with moderately elevated intraocular pressure. The examination revealed a cutaneous hemangioma of the frontal, and zygomatic area of the left half of the face, the upper and the lower eyelids, and conjunctival and episcleral hemangioma of the left eye. Since local hypotensive drug therapy produced no effect, the patient was offered a surgical treatment: sinus trabeculectomy. A pronounced hemorrhage from the conjunctival vessels, the episclera and choroidal vessels that occurred during the operation increased its duration, but severe complications could be avoided. A hyphema that appeared during the operation was almost completely washed out and dissolved within 5 days. Since scarring processes of the filtration zone were activated in the postoperative period, we resorted to an active tactics of the patient’s management, namely the needling of the filtration zone with the use of antimetabolites and corticosteroids.Conclusion. Sinus trabeculectomy is an effective method of IOP normalization in glaucoma patients with Sturge — Weber — Krabbe syndrome. Active management of the patient in the postoperative period of the case described allowed us to avoid severe intra- and postoperative complications and to achieve stable clinical and functional results.

Infrequent Giant Cutaneous Cavernous Hemangioma of the Eyelid

A 55-year-old man presented with a painless, well-circumscribed, and slowly growing mass on the right upper eyelid, present for 55 years. The mass was pedicled to the skin of the right upper eyelid. The mass was dark violet, resulting in complete mechanical ptosis and visual field occlusion (Fig A). Resection was performed via a cutaneous incision approach with an adjacent pedicled flap graft. The pathological diagnosis was cavernous hemangioma (Fig B). Most periocular cavernous hemangiomas are subcutaneous or orbital lesions, making our case an unusual presentation for this condition (Magnified version of Fig A-B is available online at www.aaojournal.org).

Diagnosis of infantile subglottic hemangioma and the effect of oral propranolol

ObjectivesTo investigate the clinical characteristics of infantile subglottic hemangioma (SGH), and to observe the safety and efficacy of propranolol in the treatment of SGH. MethodsThe data of 21 children diagnosed with SGH and treated with propranolol in our hospital from March 2013 to January 2021 were retrospectively analyzed and followed up. ResultsAmong the 21 cases, there were 7 males and 14 females. SGH was found 11 left-sided, 9 right-sided and 1 bilateral-sided. The clinical manifestations included stridor (13/21), respiratory distress (6/21), barking cough (5/21), feeding difficulty (4/21), three concave sign (4/21), cyanosis (2/21) and hoarseness (1/21). 8 patients had multiple cutaneous hemangiomas. The age of presentation ranged from 1 to 8 months, with a median of 1.1 months. 18 cases (85.7 %) had a history of misdiagnosis, 14 bronchitis/pneumonia, 5 laryngomalacia, 2 laryngeal obstruction and 1 asthma. The median ages at diagnosis were 3 months, with a range of 1.2–28 months. The treatment duration ranged from 6 to 25.6 months, with an average of (14.3 ± 4.9) months. Age at termination of treatment ranged from 9 to 38 months, with a median of 18.6 months, and only 2 cases were beyond 2 years old at that time. No adverse side effects from propranolol therapy occurred and all 21 cases were cured. ConclusionsWe advocate a strong index of suspicion for SGH presenting with respiratory symptoms under 2 years old who has poor effect or repeated condition after routine treatment. Laryngoscopy combined with contrast-enhanced CT can confirm the diagnosis of SGH. Oral propranolol is safe and effective, and that early diagnosis and intervention of propranolol without further delay are crucial to the successful management. We advocate continue propranolol treatment beyond 18 months of age, furthermore, 2 years old may be the best time for therapy termination.

Effect of Propranolol in Cutaneous and Intracavitary Hemangiomas

Objectives: The objective was to study the role of propranolol in decreasing the size and severity of hemangioma. Materials and Methods: This study was conducted in JNMC, AMU, Aligarh, India, on 100 patients who were divided according to their age group among infants (0–1 year), children (1–14 years), and adults (>14 years). Intracavitary hemangioma was diagnosed with ultrasonography/magnetic resonance imaging scan. Treatment with oral propranolol was started after ruling out any contraindication to therapy. The patients were assessed according to the Hemangioma Activity and Severity Index (HASI) at the start and at the end of treatment. The treatment outcome and side effects were recorded. Results: Among the total patients studied, there were more number of adult patients in this study, most of them were male. There were more number of patients of extracutaneous hemangioma, most of which were intra-abdominal. The difference of location of hemangioma and age group was observed, with intra-abdominal hemangiomas being more common in adult patients and cutaneous hemangioma being more common in infant and pediatric age group. The propranolol therapy was effective in all age groups, with mean HASI being reduced significantly between start and end of treatment at 16 weeks (P = 0.001). There was regression in a good number of patients with partial regression in 55% of patients and complete regression in 32.5% of patients. Minor side effects of hypoglycemia, palpitation, and episodic bradycardia were observed in very few patients. Conclusions: Propranolol is effective in reducing the size and severity of hemangiomas among all age group of patients without causing any severe side effect.

Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma.

To assess the efficacy of transcatheter arterial embolization (TAE) plus propranolol treatment for infantile hepatic hemangioma (IHH). A retrospective study of symptomatic IHH and hemodynamic changes in IHH was conducted between 2016 and 2019. There were five boys and seven girls with diffuse lesions (n = 7) and multifocal lesions (n = 5). Hepatomegaly and abdominal distension (n = 6) were the predominant clinical presentations. Seven patients (58.3%) had multiple cutaneous hemangiomas. Pulmonary arterial hypertension, heart failure (n = 4), and hypothyroidism (n = 4) were observed. A total of 17 TAE procedures were performed in 12 IHH cases, with a technical success rate of 100%. All patients received standard propranolol orally, and one patient was orally administered metacortandracin. Two patients died of heart failure and multiple organ dysfunction caused by an enlarged liver. In addition, one patient was not reexamined after discharge. Of the remaining nine children, the average follow-up time was 10.78months (range 2-28months), and they all responded well to TAE combined with oral propranolol. TAE combined with propranolol is safe and effective for the treatment of IHH, demonstrating low complication rates.

Update on Treatment of Infantile Hemangiomas: What's New in the Last Five Years?

Among benign vascular tumors of infancy, hemangiomas are the commonest, affecting approximately 5–10% of one-year-old children. They are derived from a benign proliferation of vascular endothelial cells (VECs) in the mesoderm and may arise anywhere on the body around 1–2 weeks after birth. Infantile hemangiomas (IHs) are characterized by an early proliferative phase in the first year followed by a spontaneous progressive regression within the following 5 years or longer. IH prevalence is estimated to be 5%–10% in one-year-old children and commonly affects female, Caucasian and low-birth weight infants. Although most of them spontaneously regress, approximately 10% requires treatment to prevent complications due to the site of occurrence such as bleeding, ulceration, cosmetically disfigurement, functional impairment, or life-threatening complications. For over 30 years, steroids have represented the first-line treatment for IHs, but recently topical or systemic β-blockers are increasingly being used and recognized as effective and safe. A search for “Cutaneous infantile hemangioma” [All Fields] AND “Treatment” [All Fields] was performed by using PubMed and EMBASE databases. Treatment of IHs with labeled drugs, such as oral propranolol, but also with off-label drugs, such as topical β-blockers, including topical timolol and carteolol, steroids, itraconazole or sirolimus, with a focus on formulations types and adverse events were described in our review. We also discussed the benefits of pulsed dye laser and the treatment of IHs with involvement of central nervous system, namely the PHACE and LUMBAR syndrome.

Progress in the treatment of infantile hemangioma

Infantile hemangioma (IH) is a common benign tumor, which mostly resolves spontaneously; however, children with high-risk IH need treatment. To compare the efficacy of single drug pharmacotherapy and combined drugs pharmacotherapy for a spectrum of Infantile Cutaneous Hemangiomas ranging from smaller and simpler lesions to large and complicated lesions selectively chosen. It is a Retrospective and Prospective study done for 2yrs. All children less than 2 years of age, with Infantile Cutaneous Hemangiomas. Infantile Cutaneous Hemangiomas not amenable for complete primary excision because of size and site of lesion are included in the study. Children with Infantile Cutaneous Hemangiomas presenting after 2 years of age and Hemangiomas associated with Visceral Hemangiomas. Infantile hemangiomas (IHs) are the most-common soft-tissue tumors of infancy, occurring in 4% to 10% of children under 1 year of age, with a clear female to male predominance of 2.5 – 4:1­. 27(64.2%) presented with lesion in the head and neck region. Three (3) out of the 42 presented (7.1%) on the chest. Four (4) out of the 42 (9.5%) presented on the Anterior abdominal wall.

Klippel-Trenaunay Syndrome

Klippel–Trenaunay syndrome (KTS) is a congenital, uncommon but a well-recognized disorder, characterized by cutaneous hemangiomas, varicosities, and unilateral bone and soft tissue hypertrophy with different localization. Generally diagnosed at birth or first few years of life. KTS represents a syndrome of interest for those in the field of oral and maxillofacial radiology and pathology because of high incidence of variations seen in the orofacial region in affected patients. A case of a 3-year-old female patient with KTS reported to the Department of Pedodontics and Preventive Dentistry for extraction, and we have documented and tabulated the Orodental manifestation of this patient.

The Klippel-Trénaunay Syndrome in 2022: Unravelling Its Genetic and Molecular Profile and Its Link to the Limb Overgrowth Syndromes.

The Klippel-Trénaunay syndrome is an unusual syndrome of vascular and dermatologic manifestation in which patients demonstrate hemihypertrophy of the soft tissue and bones of one limb, cutaneous haemangiomas and varicosities in anatomically abnormal positions. Described in 1900 by two French physicians, the etiology remained unclear until recently, when evidence emerged that there was a genetic basis for this sporadic disorder. Genes that encoded pathological angiogenic factors and caused vascular dysmorphogenesis, explaining the molecular bases of this syndrome, were identified. Several angiogenic genes were identified but one gene, the AGGF1 (formerly VG5Q) gene, was seen in mutations involving patients diagnosed with Klippel-Trénaunay syndrome. Furthermore, this syndrome was also noted to have overlapping clinical features linked with the “overgrowth syndromes,” in which genetic mutations along somatic lines were identified. These involved The PI3K enzyme which forms part of the phosphoinositide 3–kinase pathway which is encoded by the PIK3CA-gene. This enzyme mediates embryonic cellular growth in-utero and diseases involved in this pathway are classified as members of the PIK3CA-related overgrowth syndrome. This paper reviews the status of what is now known about the molecular genetics of this unusual, but clinically challenging disorder and its differentiation from similar diseases, linked with the PIK3CA-gene and the related overgrowth syndromes.

A Critical Review of the risk factors associated with Canine Squamous Cell Carcinoma development

Squamous cell carcinoma (SCC) is a common neoplastic skin disease that is highly prevalent in tropical countries. As the skin has a variety of cells, overexposure to environmental factors, such as ultraviolet light, can affect this organ, resulting in malignancies, such as cutaneous SCC, hemangioma, and hemangiosarcoma. SCC arises from keratinocytes in the skin and is locally invasive with low metastatic rates, commonly affecting unpigmented skin in sites with high exposure to sunlight, such as ventral regions. SCC has a variable etiology that is not well understood. Therefore, literature review aimed to critically evaluate the risk factors involved in the SCC development.

Multifocal Infantile Hemangiomas Treated by Oral Itraconazole: A Case Report

We describe a case of a 2-month-old girl presented with more than 60 papules and nodules of hemangiomas involving the skin of the sclera, endocanthion, lower lip, and labium majus pudenda without visceral hemangiomas and laboratory abnormality. A skin biopsy showed numerous scattered, clearly limited, irregular cellular lobules in the dermis circumvoluted into capillaries comprising incomplete vessel walls, which was consistent with a diagnosis of multifocal cutaneous infantile hemangioma. Oral treatment with itraconazole (5mg/kg/day) for 26 weeks resulted in predominantly involution of the skin hemangiomas. We would like to report a rare case of multifocal cutaneous infantile hemangioma, successfully treated with oral itraconazole.

Benign Neonatal Hemangiomatosis.

Benign neonatal hemangiomatosis (BNH) is a rare, self-limiting subtype of infantile hemangiomas (IHs), in which infants with multiple cutaneous hemangiomas lack visceral involvement. Other subtypes of IHs exist that may mimic BNH and can be life-threatening depending on hemangioma location and size. At birth, a 29 5 / 7 -week preterm female presented with several pinhead-sized pink papules distributed throughout her body. At 10 days of age, the patient had 12 enlarged domed-shaped red papules in a generalized distribution throughout her body. Over several weeks, the number and size of the domed-shaped red papules continued to increase to a total of 26 located on the head, chest, abdomen, back, legs and arms. They were of firm consistency with both smooth and lobulated surfaces. A diagnosis of BNH was made after extensive workup did not reveal any extracutaneous hemangiomas. Due to the lack of extracutaneous involvement and low-risk location/size of hemangiomas in our patient, no interventions were pursued and an observation-only approach was implemented. The patient remained stable while followed up over 8 months, with the size of the hemangiomas only increasing slightly in proportion to the patient's natural body growth. Given the life-threatening nature of certain hemangioma subtypes, it is important to implement a proper workup and subtype diagnosis as early as possible in any infant with multiple hemangiomas.

PHACE syndrome: a frequently overlooked entity

<p>Infantile hemangiomas are the commonest vascular tumors of infancy. About 10% are associated with PHACE syndrome, a rare condition presenting with multiple systemic anomalies along with large cervicofacial hemangiomas<strong>.</strong> We present two case reports of this rare entity. First, a six year old female, with cutaneous hemangiomas involving the face and oral cavity, and extracutaneous hemangiomas involving the parotid glands, choroid and peripapillary region of the eye. MRI brain revealed presence of vascular malformations in the circle of Willis along with impingement of optic nerve. MRI head and neck region confirmed the presence of hemangiomas in bilateral parotid gland, right upper eyelid near medial canthus and in the suprasternal region. Second, a three-month-old female presenting with stridor along with hemangiomas involving segment 3 of face, oral cavity and parotid glands. CECT neck and Chest showed hemangiomas involving bilateral parotid and submandibular glands. Mediastinal involvement with extraluminal compression of airway was noted. Microlaryngobronchoscopy did not reveal presence of any airway hemangiomas. Ophthalmological examination showed signs of optic nerve hypoplasia. In both the cases, all the clinico-radiological findings were put together to establish the diagnosis. Both of them also showed significant response to the oral propranolol therapy. Due to the rarity and overlapping features of this syndrome, there is a high chance to overlook this diagnosis. A high index of suspicion and awareness about the features is needed to identify this condition and provide specific treatment.</p>

Uncomplicated Cutaneous Infantile Strawberry Hemangioma: Educational Images and Evidence-Based Recommendation

Uncomplicated Cutaneous Infantile Strawberry Hemangioma: Educational Images and Evidence-Based Recommendation

Spontaneous evolution patterns of focal congenital hepatic hemangiomas: a case series of 25 patients.

Hepatic hemangiomas are the most common benign liver tumors of infancy. They are termed congenital if fully developed at birth or infantile if they appear in the first weeks of life. Previous studies suggested that most focal hepatic hemangiomas are congenital in nature, exhibit no postnatal growth and have an evolution that parallels their cutaneous counterparts. They are subdivided by pattern of involution, whether rapidly involuting (RICH), partially involuting (PICH) or non-involuting (NICH) congenital hemangiomas. In our experience, some focal hepatic hemangiomas show postnatal growth, behaving like infantile forms. To analyze the spontaneous evolution of focal congenital hepatic hemangiomas with quantification of tumor volume changes over time and to identify initial postnatal ultrasound (US) imaging biomarkers predictive of their evolution pattern. A retrospective review of clinical, imaging and pathology data of children diagnosed with focal congenital hepatic hemangioma (prenatal diagnosis or age at diagnosis <7days and/or glucose transporter protein 1 [GLUT1]-negative tumor) diagnosed between 2000 and 2018 was performed with analysis of tumor volume changes over time. Exclusion criteria were treatment inducing a tumor volume change (hepatic artery embolization, propranolol, or corticosteroids), imaging follow-up less than 1month or fewer than two US examinations. Volumetric analysis was based on US and cross-sectional imaging. Lesion volumes were estimated using the standard ellipsoid formula. A 35% margin of error was assumed for tumor volume variation to account for variability in measurements. Imaging studies, including US, computed tomography, and magnetic resonance imaging, were reviewed and initial postnatal US features were correlated with evolution pattern. Twenty-five patients with focal congenital hepatic hemangiomas were included. The median follow-up time was 46.5months (range: 4-144months). Eight (32%) lesions showed postnatal growth before involuting, without signs of intralesional hemorrhage, as do cutaneous infantile hemangiomas. The other 17 (68%) lesions exhibited a strict decrease in volume with age, of which 15 underwent complete involution (8 before age 18months and 7 after age 18months) and 2 underwent partial involution. The different evolution patterns of focal congenital hepatic hemangiomas showed overlapping imaging features and we found no initial US feature to be significantly associated with postnatal growth. However, large vascular spaces with marked vascularity at US were noted in three of the eight rapidly involuting lesions. Focal congenital hepatic hemangiomas are not the equivalent of cutaneous RICH, as some may increase in size and tumor regression may be rapid or slow. The different evolution patterns of focal congenital hepatic hemangiomas show overlapping US features.

Clinical Profile of Paediatric Hemangiomas, Response to Oral Propranolol, and Comparison of Intralesional Bleomycin and Triamcinolone in Propranolol Non Responders at a Tertiary Care Center in North India.

Background:A paradigm shift has occurred regarding the treatment of cutaneous hemangiomas over the last few years, from an open surgical approach to a conservative or minimally invasive approach. There are various treatment modalities described, and response to them is variable and unpredictable. This study was conducted to study the clinical profile of children with uncomplicated cutaneous hemangiomas, their response to oral propranolol, and compare intralesional bleomycin and intralesional triamcinolone among nonresponders to propranolol.Materials and Methods:A trial was conducted among 158 children <12 years with cutaneous hemangiomas from January 2019 to October 2020 in Kanpur, Uttar Pradesh. Based on the response to propranolol, partial/nonresponders were later assigned randomly to either receive intralesional bleomycin (n = 30) or intralesional triamcinolone (n = 29). Response to treatment and complications were assessed in two groups. All children were followed up for 6 months.Results:Of 158 children, complete response to propranolol was found in 99 (62.7% [95% confidence interval (CI): 54.6%–70.1%]) children. Partial and no response was found in 33 (20.9% [95% CI: 15.0%–28.2%]) and 26 (95% CI: 16.5% [11.2%–23.4%]) children, respectively. In the bleomycin group, 66.7%, 23.3%, and 10.0% of patients showed excellent, good, and poor response, respectively, and in the triamcinolone group, 27.6%, 24.1%, and 48.3% showed excellent, good, and poor response, respectively (P = 0.002). However, there was no significant difference between them in terms of complications.Conclusion:Intralesional bleomycin was found to be a better drug in terms of response compared to triamcinolone. There are no significant differences in complications between them. Further studies are needed to further evaluate the combined efficacy of bleomycin with triamcinolone and other treatment modalities.

Clinical Analysis of Color Doppler Ultrasound Combined with Propranolol in the Treatment of Infantile Cutaneous Hemangioma

To investigate the efficacy of color Doppler ultrasound combined with propranolol in the treatment of infantile vascular cancer is the objective of the study. 126 children with vascular cancer in the Department of Dermatology of a provincial hospital were randomly divided into ultrasound, propranolol and conventional systematic treatment. Compared with the control group, the experimental group could master more detailed and comprehensive information on the volume, depth and elasticity of hemangioma and the size of hemangioma in the experimental group decreased by 38.5 % after 1 mo of treatment and 59.7 % after 3 mo of treatment. The coagulation function of blood vessels recovered and the blood flow velocity increased by 22.3 % compared with that before treatment. The effect of rehabilitation treatment was significantly better than that of the control group (76.49 %>62.35 %). There was significant difference between the two groups in adverse reactions such as blister (p=0.146), infection (p=0.027), pigment change (p=0.033), scar (p=0.032) and rash (p=0.007) (p<0.05). The average treatment effect of vascular cancer in the experimental group was 94.55 %, which had significant statistical significance in the recovery of physical function and coordination of patients (p<0.05), and the median survival time and quality of life were significantly different from those in the control group (p<0.05). Ultrasound combined with propranolol can effectively improve the condition of infant vascular cancer, contribute to the later rehabilitation treatment and improve the quality of life.